Comparison of 24-Hour Intraocular Pressure Reduction Obtained with Brinzolamide/Timolol or Brimonidine/Timolol Fixed-Combination Adjunctive to Travoprost Therapy

Konstas, Anastasios G. P.; Holló, Gábor; Haidich, Anna Bettina; Mikropoulos, Dimitrios G.; Giannopoulos, Theodoros; Voudouragkaki, Irini C.; Paschalinou, Eleni; Konidaris, Vasileios; Samples, John R.

doi:10.1089/jop.2012.0195

Cited by 22 publications

(31 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16 Further, fixed-combination brinzolamide/timolol or brimonidine/timolol added to travoprost reduced IOP from travoprost-treated baseline (20.1 mm Hg) by 14 and 10%, respectively, after 3 months. 6 In the current study, BBFC+PGA produced a mean diurnal IOP reduction of 25% at week 6 (compared with 8% in the vehicle+PGA group), suggesting that BBFC added to a PGA may produce IOP reductions similar to those observed in prior studies of a three-agent treatment regimen that included a β -blocker.…”

Section: Discussionsupporting

confidence: 71%

“…3 As many as 50% of patients in the Ocular Hypertension Treatment Study required additional ocular hypotensive medications to maintain IOP reduction after the first year of treatment. 4 Although the safety and efficacy of adding a fixed-combination medication containing timolol to prostaglandin monotherapy have been demonstrated, 5, 6, 7 data are needed to evaluate the addition of a fixed combination without a β -blocker to PGAs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial

Fechtner

Myers

Hubatsch

et al. 2016

Eye

View full text Add to dashboard Cite

PurposeTo determine whether intraocular pressure (IOP) lowering with fixed-combination brinzolamide/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA) was superior to that of vehicle+PGA in patients with open-angle glaucoma or ocular hypertension who were inadequately controlled with PGA monotherapyMethodsThis 6-week, multicenter, randomized, double-masked, parallel-group trial was conducted at 30 clinical sites in the United States between October 2013 and May 2014. Eligible patients were adults with open-angle glaucoma or ocular hypertension and with mean IOP ≥21 and <32 mm Hg, whereas receiving an open-label PGA (latanoprost, bimatoprost, or travoprost). Patients instilled a PGA once-daily in a run-in phase before randomization to masked BBFC or vehicle adjunctive treatment. Masked treatments were instilled 3 times daily for 6 weeks, and patients continued once-daily use of their PGA. The primary efficacy end point was the between-group difference in mean diurnal IOP (average of 0800, 1000, 1500, and 1700 hours time points) at week 6.ResultsAt week 6, mean diurnal IOP with BBFC+PGA was lower than with vehicle+PGA (17.1±0.4 mm Hg vs 20.5±0.4 mm Hg; between-group difference, −3.4±0.5 mm Hg; P<0.0001; 95% confidence interval, −4.5 to −2.4 mm Hg). BBFC+PGA reduced mean diurnal IOP by 5.7 mm Hg (25%) from the baseline IOP achieved with PGA monotherapy.ConclusionsTherapy with BBFC produced an additive IOP-lowering effect compared with a PGA alone or in conjunction with vehicle. BBFC may provide an effective treatment option for patients receiving PGA monotherapy who require additional IOP reduction.

show abstract

Section: Discussionsupporting

confidence: 71%

Section: Introductionmentioning

confidence: 99%

Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial

Fechtner

Myers

Hubatsch

et al. 2016

Eye

View full text Add to dashboard Cite

show abstract

“…While the study facility in which baseline and/or eligibility visits were conducted varied between studies (e.g., office, clinic, hospital), subject hospitalization for the 24-hour study visits was the most common approach. 27,42,44,47e61,64e66,91,98,100e104,108,109,111,115,118,122,137 Other studies specified that the 24-hour visits were conducted at an eye clinic, 19,114,132 a private room at a clinical and translational research center, 116 at the participating academic center(s), 45,46,62,63 at a hotel, 26 or in a sleep laboratory setting. 22,81,84,85,119,128,133 Although most subjects were hospitalized for 24-hour assessments, a drug comparison study conducted by Yildirim and coworkers noted that most patients wanted to avoid being hospitalized overnight.…”

Section: Study Design and Maskingmentioning

confidence: 99%

Review of the measurement and management of 24-hour intraocular pressure in patients with glaucoma

Mansouri

Tanna

Moraes

et al. 2020

Survey of Ophthalmology

View full text Add to dashboard Cite

Elevated intraocular pressure (IOP) is a major, and currently the only, modifiable risk factor that has been shown to reduce the risk of glaucoma onset and progression. Diurnal measurements of IOP, usually during office hours, are commonly used for the assessment of IOP variation and the relative success of medical, laser, or surgical IOP-lowering interventions. Such measurements, however, fail to capture variation in IOP over the day/ night cycle, which may be influenced by factors such as body position. We examine current evidence in the field of IOP measurement and controldwith a focus on 24-hour (circadian) study design and measurement techniques and the 24-hour efficacy of current treatmentsdin patients with glaucoma and ocular hypertension. We then provide our recommendations for the design of future studies of circadian IOP with the aim of improving the assessment, management, and treatment of patients with glaucoma and ocular hypertension.

show abstract

“…[63]. При этом максимальный режим терапии, предусматривающий применение комбинации трех действующих веществ -бринзоламида, тимолола, травопроста (Азарга, Траватан), привел к сглаживанию суточных колебаний значений ВГД [64].…”

unclassified

“…В последние годы активно изучается роль фиксированных комбинаций в лечении глаукомы при назначении максимального и ультрамаксимального гипотензивного режима, который предполагает использование трех и даже четырех действующих веществ с разным механизмом действия для достижения целевого ВГД [74,75]. Результаты этих исследований демонстрируют, в каком направлении продолжает эволюционировать медикаментозное лечение глаукомы.…”

unclassified

The role of fixed dose combinations in the treatment of primary open-angle glaucoma

2018

View full text Add to dashboard Cite

A great number of patients with primary open-angle glaucoma require combination therapy with several hypotensive drugs of different pharmacological groups to efficiently compensate the intraocular pressure (IOP) and prevent further development of glaucoma. Although glaucoma treatment usually starts with monotherapy, several preparations administered simultaneously have stronger hypotensive effect further increased by their additive action. However, the increased frequency of instillations may lead to drug washout and decreased patient compliance. Fixed dose combinations (FDCs) are a pharmacological form of eye drops that combines two or more active drugs in a single dosage form. The frequency of FDCs administration does not exceed two per day, which is convenient for long-term application and helps improve patient compliance. FDCs tolerability tends to be higher than that of simultaneous instillations of separate monotherapy drugs, while the hypotensive in clinical trials is comparable, in some real practice trials is superior. A review of existing studies showed that FDCs are superior to monotherapy in terms of cost-effectiveness. The use of FDCs was found to be beneficial for glaucoma treatment from the viewpoints of both reaching the target IOP for preserving visual functions in glaucoma patients, and minimizing the long-term treatment costs.

show abstract

Comparison of 24-Hour Intraocular Pressure Reduction Obtained with Brinzolamide/Timolol or Brimonidine/Timolol Fixed-Combination Adjunctive to Travoprost Therapy

Abstract: This study demonstrated that both FCs provide statistically and clinically significant incremental 24-h IOP lowering to travoprost monotherapy. The brinzolamide/timolol FC however achieves a better mean 24-h IOP control owing to the greater efficacy in late afternoon and during the night.

Cited by 22 publications

References 25 publications

Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial

Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial

Review of the measurement and management of 24-hour intraocular pressure in patients with glaucoma

The role of fixed dose combinations in the treatment of primary open-angle glaucoma

Contact Info

Product

Resources

About